Given previous reports of NB’s susceptibility to BET and PARP inhibitors in preclinical models testing each drug class individually [5, 6, 10, 11, 16], we hypothesized that JQ1, a BET inhibitor, would promote a DNA repair-deficient phenotype that would function synergistically with Olaparib, a PARP inhibitor, to inhibit NB tumorigenesis. This evidence concerns the gene PARP1 and neuroblastoma.